We have detected frequent alternative splicing of a gene that encodes NER, a protein homologous to the retinoic acid receptors, in cancer cells. Western and immunohistochemical analyses disclosed accumulation of a large amount of the aberrant NER product, generated by alternative splicing that caused skipping of an exon corresponding to the DNA-binding domain, in the nucleoli of cells of cancer cell lines and primary cancer tissues. The aberrant protein was detected in 116 of 228 primary cancers developed in various tissues including breast and colon, but was absent in the corresponding normal tissues; it was also detected in 31 of 39 cancer cell lines. This observation may imply that the aberrant NER product has some relation to the development and/or progression of cancers in a variety of human tissues.
Keywords: nuclear hormone receptor; alternative splicing; cancer cell lines and primary cancers; NER Nuclear hormone receptors carry domains that are evolutionarily conserved among a wide variety of species. The common modular structure of this family of receptors includes a highly conserved DNA-binding domain and a less conserved C-terminal region that binds lipophilic ligands such as steroid hormones, retinoic acids, thyroid hormones, or ecdysone (Evans, 1988; Forman and Samuels, 1990; Baniahmad and Tsai, 1993) . These ligands play vital roles in development, dierentiation, and homeostasis, and are also known to be related to oncogenesis (Evans, 1988) . For example, in vertebrates the vitamin A derivative retinoic acid is involved in axial patterning and epithelial dierentiation at physiological doses, and at pharmacological doses is highly teratogenic (Ragsdale and Brockes, 1991; Tabin, 1991) . The major biological actions of these hormones are mediated by ligand-dependent transcription-factors. Since the receptors bind to speci®c target DNA sequences as hormone response elements, activation or suppression of downstream-gene expression occurs in a ligand-dependent manner (Beato, 1989) .
We have been performing large-scale DNA sequencing of cDNA clones from fetal lung and other tissues to identify novel cDNAs of biological or medical importance (Sudo et al., 1994) . By comparing these cDNAs with known nucleotide sequences in the public database, we found a novel human cDNA whose predicted product showed a high dose of homology to nuclear hormone receptors and was later found to be identical to the NER protein reported by Shinar et al. (1994) . To investigate a possible role of this gene in human carcinogenesis, we determined its genomic structure, raised a monoclonal antibody speci®c for the gene product, and examined alteration of NER in human cancer cell lines and in primary cancers.
Detection of aberrant protein product by Western analysis
First, we performed Western-blotting analyses using a monoclonal antibody to NER. As shown in Figure 1a , large amounts of a 40 kD NER product were present in colorectal and esophageal cancer cell lines and Hela cells, but not in normal colorectal or esophageal tissues. Neither normal tissues nor cancer cell lines contained detectable amounts of the normal protein, whose size on the basis of published cDNA sequences was estimated to be 51 kD. To examine whether the aberrant protein was produced speci®cally in cancer cell lines, we also investigated primary carcinomas of the breast, colon, ovary, esophagus, and stomach (Figure 1b) . Although the amount of the 40 kD product was less than that observed in cancer-cell lines, primary cancers were also found to contain the 40 kD protein. However, none of the corresponding normal tissues expressed this product. 
RT ± PCR experiments
To investigate the genetic mechanism generating the 40 kD protein, we performed RT ± PCR experiments using mRNAs isolated from 11 cancer-cell lines. We divided the coding region into three overlapping segments and ampli®ed each segment using the primers described in the`Experimental Procedures' section. No alterations were observed in the segments corresponding to exons 6 ± 8 or 8 ± 10. However, when the segment corresponding to exons 3 ± 6 was ampli®ed, a smaller PCR fragment that was not present in normal tissues was observed in all 11 cancer cell lines ( Figure 2a ). We performed direct DNA sequencing of the smaller fragment from each cell line, and found that this product lacked exon 5, which encodes a region corresponding to a DNA-binding domain, possibly as a result of alternative splicing (Figure 2b and c). As this exon consists of 291 nucleotides, the variant transcript is expected to lose 97 amino acids and this would account for the 40 kD product. We also examined genetic alteration or DNA rearrangement associated with this alternative splicing by SSCP analysis and Southern hybridization, but no change was detected (data not shown).
Our results raised a question as to why no normal protein was detectable in normal tissues or cancer cell Figure 2 Genetic analysis of NER. (a) RT ± PCR analysis (corresponding to exons 3 ± 6) of transcripts isolated from colorectal and oesophageal cancer cell lines. Lanes 1 and 2, normal colon tissue; lanes 3 ± 7, colorectal cancer cell line (SNUC4, SNUC5, NCIH498, NCIH508, and NCIH630); lanes 8 ± 13, esophageal cancer cell line (TE1, 2, 6, 7, 8 and 9). (b) DNA sequencing of the RT ± PCR products. N, a normal-size PCR product, T, a smaller PCR product. (c) Genomic structure of the NER gene. N, normal transcript; T, tumor-speci®c transcript.
Open boxes indicate exons protein would be very stable, or that an excess of the smaller protein might lead to rapid degradation of normal NER.
Immunohistochemical analysis
A comparison of the results from RT ± PCR analysis and Western blotting seemed to indicate that the protein lacking the DNA-binding domain accumulates in cancer-cell lines. We examined intracellular localization of normal and aberrant NER products by immunohistochemical staining. In Hela cells ( Figure  3a and b), very strong immunohistochemical staining was observed in areas corresponding to the nucleoli, indicating that the aberrant 40 kD protein which lacked the DNA binding domain and probably lost the binding activity to DNA, was accumulated speci®cally in nucleoli. In a preparation of primary colon-cancer tissue, strong immunohistochemical staining was also concentrated in the nucleoli of cancer cells (Figure 3d ), while relatively faint staining was observed in corresponding normal tissues (Figure 3e ). These results suggest that accumulation of the aberrant protein occurred during development or progression of cancer. We examined seven additional primary colon cancers, and in ®ve materials we detected strong immunohistochemical stains that were concentrated in the nucleoli of cancer cells. We have shown here the frequent alternative splicing of the NER gene, in cancer cell lines as well as in primary cancers developed in the breast, colon, and ovary. The NER gene encodes a protein homologous to members of the steroid hormone receptor family, and the peptide sequence of the DNA-binding domain of NER is 50 ± 56% identical to those of the family members and that of the ligand-binding domain is 20 ± 40% identical (Huang et al., 1988) . Among them, NER shows the highest homology to the retinoic acid receptors, which are known to play a critical role in leukemia. In this report, we demonstrated that nearly 80% of cancer cell lines, and more than half of the 123 primary cancers of the breast, colon, and ovary contained the aberrant protein that was generated by alternative splicing and lacked the DNA binding domain. It is notable that the incidence of alternative splicing in these cancers, that may be associated with the fatty diet, is much higher than that in esophageal and gastric cancers. These results suggest that the alternative splicing observed in the NER gene may be related to the hormonal condition in each cancer tissue. Furthermore, it is also interesting that the frequency and amount of the aberrant NER protein observed in cancer cell lines derived from colon, esophagus, and gastric cancers were much higher than those observed in primary colon, esophagus, and gastric cancers. Hence, to further examine the relation of alternative splicing to stage, histological grade, or metastasis of cancer is very important to investigate a possible role of NER.
Considering this mechanism and the evidence that the ligand of the retinoic acid receptor, the retinoic acid, is very eective for treatment of the leukemia patients with t(15;17) (Huang et al., 1988) , the ligand of NER, although it was not yet identi®ed, might be a potentially useful drug for treatment of the patients with cancers in which the aberrant protein is overproduced. The evidence of very high rate of alternative splicing observed only in cancer tissues (not only cancer cell lines but also primary cancers) without DNA alteration may be very important for the future direction of cancer treatment because somatic DNA changes in tumors are probably irreversible, but epigenetic changes are possibly reversible.
The mechanism causing the alternative splicing is unknown. However, a similar phenomenon has been reported in the case of CD44; a CD44 transcript spliced alternatively produces a smaller molecularweight protein which is thought to be related to metastasis (Grioen et al., 1994) . Multiple isoforms of CD44 are dierentially glycosylated in the extracellular domain. In the case of NER, although it is unclear whether the product lacking the DNA-binding domain is able to bind to the ligand, certain the molecule is unable to bind to the response element(s) of the transcriptionally regulated target gene(s). As it is possible that deregulation of the target gene may stimulate cell growth and result in progression of cancer to further investigate its ligand, and the role of normal and aberrant proteins in cell growth is crucial to know its potential usefulness in clinical ®eld.
Materials and methods

Tumor samples
Tumor samples and their corresponding normal tissues were obtained at surgery on patients with colon, breast, ovarian, gastric, or esophageal cancer. The surgery was underwent at the Cancer Institute Hospital (Tokyo, Japan) or Tohoku University Hospital (Miyagi, Japan). Upon surgical removal, samples were frozen in liquid nitrogen. Esophageal and colorectal cancers cell lines were established by two of the co-authors (TN and J-GP).
Antibody
Female Balb/c mice were immunized by subcutaneous injection three times every 2 weeks with 100 mg of GST-NER fusion protein which had been expressed in E coli and puri®ed with glutathione sepharose 4B. After the last immunization, murine splenocytes were fused to myeloma cells (P3U1) and cultured for 10 to 14 days. Hybridomas were screened for anti-NER reactivity by ELISA, using GST-NER coated plates. Puri®ed GST-coated plates were used as a negative control in ELISA. Positive hybridomas were subcloned twice by limiting dilution and a few clones were established. The reactivity of the antibody was blocked by preincubation of an excess amount of puri®ed NER protein with the antibody, indicating that the antibody reacts with NER. Furthermore, the experiment using the partial NER proteins that were synthesized in E coli revealed that the antibody recognized an epitope present in the N-terminal 60 amino acids.
Western blotting analysis
A 30 microgram aliquot of each protein lysate from tissues or cultured cells was electrophoresed on a 0.1% SDS-10% polyacrylamide gel, and fractionated proteins were transfered to polyvinylidene di¯uoride membrane using a semi-dry blotter. The ®lter was blocked with 10% nonfat dried milk, 0.05% Tween 20 in TBS for 1 h. After incubtion of 1 mg/ml anti-NER antibody in a mixture of 5% nonfat dried milk and 0.05% Tween 20 in TBS for 1 h, the ®lters were washed for 15 min with three changes of 0.05% Tween 20 in TBS. Horseradish peroxidase-conjugated goat anti-mouse antibodies (0.1 mg/ml in 5% nonfat dried milk, 0.05% Tween 20 in TBS) were incubated with the ®lters for 1 h. The ®lters were then washed for 15 min with six changes of 0.05% Tween 20 in TBS. Peroxidase activity was detected by means of Amersham's ECL according to the manufacturer's protocol. cDNA cloning and DNA sequencing As a part of the Human Genome Project, we have been determining nucleotide sequences of cDNA clones randomly selected from a directionally-cloned cDNA library that was constructed from fetal-lung mRNA purchased from Clontech (La Jolla, CA) using a ZAP-cDNA Synthesis Kit (Stratagene). We determine nucleotide sequences by the dideoxy chain-termination method (Sanger et al., 1977) using T3, T7, or synthetic oligonucleotide primers. By comparing 5' partial sequences of our selected cDNA clones with known nucleotide sequences in the public database, we identi®ed one cDNA clone with a predicted product homologous to nuclear hormone receptors. As this original clone lacked the 5' portion of the transcript, we performed plaque hybridization in a breast-cDNA library (Clonetech, La Jolla, CA), using an insert consisting of about 1.4 kb of the original cDNA clone as the probe, and isolated ten additional cDNA clones. The clone with the largest insert was sequenced. With this cDNA as the probe, genomic clones were isolated from a total human genomic cosmid library (®ve-genome equivalent). The genomic structure of the NER gene, including the exon-intron boundaries, was determined by Southern analysis and DNA sequence analysis of the selected cosmid clone, using several primers corresponding to cDNA sequences. Nucleotide sequences were determined by the dideoxy chain-termination method (Sanger et al., 1977) using 35S-dATP.
RT ± PCR experiments
Total RNAs from cells or tissues were isolated using ISOGEN (Nippon Gene Ltd.) according to the manufacturer's instructions, and mRNAs were reversetranscribed with dT 15 primer for single-stranded cDNA synthesis. The cDNAs were ampli®ed by the polymerase chain reaction (PCR) as follows: initial denaturation at 958C for 2 min, followed by 35 cycles of 948C for 30 s, 638C for 30 s, and 728C for 30 s, and incubation at 728C for 5 min. The primers for ampli®cation of exons 3 ± 6 were 5'-ATGTCCTCTCCTACCACGAGTT-3' (forward) and 5'-TGCGACTGTGACT GTGACTCC-3' (reverse); those for exons 6 ± 8 were 5'-CCGGAAGAA-GAAGATTCGGAAAC-3' and 5'-CCTGCAGGCCTGC-ACGGTG-3', and primers for exons 8 ± 10 were 5'-ACC-TACAGCAAGGACGACTTCC-3' and 5'-GGAGGGTG-GTCAGGCAAGGC-3'. All PCR products were electrophoresed on 2% agarose gels.
Immunohistochemical analysis
Hela cells grown on slides for 2 days were ®xed with 4% paraformaldehyde for 10 min at room temperature and washed with PBS three times for 10 min. Slides were treated with 0.1% tritonX-100/PBS solution for 10 min to permeabilize the cells, then soaked in a solution containing 10% fetal bovine serum in PBS for 10 min. Anti NER antibody (1 mg/ml in PBS) was then added to the slides, which were incubated for 1 h at room temperature and then washed three times with PBS for 10 min. FITClabeled goat anti-mouse antibody (1/200 dilution in PBS) was added, and the slides were incubated in the dark at room temperature for 1 h. Cells were washed three times with PBS for 10 min each time, and examined under ā uorescence microscope. Frozen colonic tissue containing a well-dierentiated colorectal adenocarcinoma was embedded in OCT (Miles Laboratories, Inc.) and cut into 5 mm-thick slices. The sections were immediately ®xed in 4% paraformaldehyde for 30 min at 48C and stained immunohistochemically as described above. The sections were also stained with hematoxylin and eosin by conventional methods.
